Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Selank
Also known as: TP-7, Selanc
Selank is a synthetic heptapeptide analog of the immunomodulatory peptide tuftsin, developed in Russia and approved there as an anxiolytic and nootropic medication. It exhibits anti-anxiety effects comparable to benzodiazepines without the sedation, cognitive impairment, or addiction potential. It also has immunomodulatory properties that distinguish it from conventional anxiolytics.
Risk Level
Low RiskDifficulty
Beginner| CAS Number | 129954-34-3 |
| Molecular Formula | C33H57N11O9 |
| Class | Peptide |
| Category | Well-Known Peptides |
Mechanism of Action
Selank modulates GABAergic neurotransmission and enhances the expression of the GABA-A receptor, producing anxiolytic effects without direct benzodiazepine-like receptor binding. It influences the balance of T-helper cytokines and modulates interleukin-6, contributing to its immunomodulatory profile. The peptide also affects the metabolism of monoamines including serotonin and enkephalins, and stabilizes enkephalin degradation in the blood.
Dosing Research
Standard intranasal dosing is 250-500 mcg per day divided into 2-3 administrations. Clinical protocols in Russia typically run 10-14 day courses. Subcutaneous administration at similar doses has also been explored in research settings.
Side Effects & Risks
Very well tolerated with a favorable safety profile. Mild nasal irritation may occur with intranasal use. No sedation, dependence, or withdrawal symptoms have been reported, in contrast to benzodiazepines. Rare reports of fatigue and mild headache exist.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.